Trial · NCT00578552
Gabapentin for Smoking Cessation
NCT00578552, Phase 2, Completed, Mayo Clinic; results first posted 2010-12-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gabapentin for Smoking Cessation. Trials, record NCT00578552. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00578552
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gabapentin for Smoking Cessation
- NCT number
- NCT00578552
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 80 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Cigarette Smoking, Tobacco Use
- Interventions
- Placebo, Gabapentin - 1800 mg/day, Gabapentin - 2700 mg/day
- First posted
- 2007-12-21
- Last updated
- 2011-04-19
- Results first posted
- 2010-12-01
- Limitations and caveats
The original intent was to enroll a total of 120 subjects. However, due to the high study dropout rate, a review of the primary endpoint was performed after 80 subjects were enrolled and a decision was made to discontinue further enrollment.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco | 12 weeks following start of medication | Point prevalence tobacco abstinence was adjudicated if the following conditions were met: (a) self-reported tobacco abstinence for the previous 7 days with a negative response to the question "Have you used any type of tobacco, even a puff, in the past 7 days?" and (b) Expired Carbon Monoxide equal or less then 8 parts per million. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco | 12 weeks following start of medication | participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco | Placebo | 5 | participants | ||
| Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco | Gabapentin - 1800 mg /Day | 4 | participants | ||
| Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco | Gabapentin - 2700 mg/Day | 0 | participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 27 | |
| Overall Study | STARTED | Gabapentin - 1800 mg /Day | 27 | |
| Overall Study | STARTED | Gabapentin - 2700 mg/Day | 26 | |
| Overall Study | COMPLETED | Placebo | 12 | |
| Overall Study | COMPLETED | Gabapentin - 1800 mg /Day | 13 | |
| Overall Study | COMPLETED | Gabapentin - 2700 mg/Day | 11 | |
| Overall Study | NOT COMPLETED | Placebo | 15 | |
| Overall Study | NOT COMPLETED | Gabapentin - 1800 mg /Day | 14 | |
| Overall Study | NOT COMPLETED | Gabapentin - 2700 mg/Day | 15 |
Source ClinicalTrials.gov
Adverse events45
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | General disorders | Placebo | 1 | 27 | |
| other | Dizziness | General disorders | Gabapentin - 1800 mg /Day | 4 | 27 | |
| other | Dizziness | General disorders | Gabapentin - 2700 mg/Day | 4 | 26 | |
| other | Decreased Concentration | General disorders | Placebo | 0 | 27 | |
| other | Decreased Concentration | General disorders | Gabapentin - 1800 mg /Day | 3 | 27 | |
| other | Decreased Concentration | General disorders | Gabapentin - 2700 mg/Day | 0 | 26 | |
| other | Edema | General disorders | Placebo | 1 | 27 | |
| other | Edema | General disorders | Gabapentin - 1800 mg /Day | 2 | 27 | |
| other | Edema | General disorders | Gabapentin - 2700 mg/Day | 0 | 26 | |
| other | Sleep Disturbance | General disorders | Placebo | 3 | 27 |
1 to 10 of 45Source ClinicalTrials.gov
See all 45 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Gabapentin - 1800 mg /Day | ||
| Total, all-cause mortality | Gabapentin - 2700 mg/Day | ||
| Total, other adverse events | Placebo | 5 | 27 |
| Total, other adverse events | Gabapentin - 1800 mg /Day | 12 | 27 |
| Total, other adverse events | Gabapentin - 2700 mg/Day | 7 | 26 |
| Total, serious adverse events | Placebo | 1 | 27 |
| Total, serious adverse events | Gabapentin - 1800 mg /Day | 0 | 27 |
| Total, serious adverse events | Gabapentin - 2700 mg/Day | 1 | 26 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20081039 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00578552
GET https://conductscience.org/api/trials/v1/NCT00578552/events?page=2